Item 5. Other Information
Item 5. Other Information
None.
Item 6. Exhibits.
Number
Description of Document
31.1
Statement of CEO Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*
31.2
Statement of CFO Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*
32.1
Statement of CEO Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002**
32.2
Statement of CFO Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002**
101.INS
Inline XBRL Instance Document*
101.SCH
Inline XBRL Taxonomy Extension Schema Document*
101.CAL
Inline XBRL Calculation Linkbase Document*
101.DEF
Inline XBRL Taxonomy Extension Definition Linkbase Document*
101.LAB
Inline XBRL Label Linkbase Document*
101.PRE
Inline XBRL Taxonomy Presentation Linkbase Document*
104
Cover Page Interactive Data File—the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document
*
Filed herewith.
**
Furnished, not filed.
33
Table of Contents
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on our behalf by the undersigned thereunto duly authorized.
Benitec Biopharma Inc.
Dated: May 16, 2022
/s/ Jerel Banks
Jerel Banks
Executive Chairman and Chief Executive Officer
(principal executive officer)
/s/ Megan Boston
Megan Boston
Executive Director (principal financial and accounting officer)
34
Text extracted from the filing as submitted to EDGAR. Formatting, tables and exhibits are simplified for reading; the original document is authoritative for anything you rely on.